Follow IQVIA Holdings to never miss an important update.
The company's AI-enabled tool, developed with the nonprofit Breakthrough T1D, was named the predictive modeling solution of the year. The software uses healthcare-grade AI to help doctors and researchers make better decisions during clinical trials, which are the long and expensive tests required to prove a new drug is safe. While a single award is not a major financial event, it validates the company's push to use software to make research more efficient. IQVIA's ability to win more contracts depends on proving that its technology can find the right patients and predict outcomes faster than traditional methods.
Source: Business Wire
The company is collaborating with Medera to help develop new treatments for cardiovascular disease. This partnership uses the company's research services and data to help find and test new drugs more quickly.
For a long-term owner, this is a clear example of the company's core strategy in action. By acting as the research partner for biotech firms, it earns revenue from the work while making its own health data more valuable. These kinds of partnerships help ensure the company remains a central part of how new drugs reach the market.
Source: Business Wire
BMO Capital raised its target price from $210 to $270 while keeping its positive rating. This change follows the company's recent report of higher sales and profits than analysts had expected.
This is a significant jump in the target price and suggests the firm sees more value in the company's large backlog of signed contracts. When analysts raise targets this much, it often means they believe the company's ability to turn those future contracts into actual cash is getting more reliable.
Source: BMO Capital
The company reported adjusted earnings of $3.15 per share, which was higher than the $3.03 analysts expected. Revenue grew about 9 percent to $4.37 billion, also topping expectations. The stock rose about 11 percent after the news.
The most important detail for long-term owners is the growth in new bookings, which rose 19 percent compared to last year. This adds to the company's massive backlog of signed contracts, which provides a clear view of where future revenue will come from. Because drugmakers are continuing to hire the company to run their clinical trials, management felt confident enough to raise its financial goals for the rest of the year.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
Dr. Cynthia Verst testified before a House subcommittee, offering recommendations to make early clinical trials more efficient in the United States. The goal is to help the U.S. remain a top destination for pharmaceutical research. While this doesn't change the company's finances today, it shows its role as an advisor to the government. If rules change to make trials easier to run, it could lead to more work for the company, as it is the largest player in the industry helping drugmakers navigate these regulations.
Source: Business Wire
Analysts recently issued a flurry of positive updates, including several price target increases at the end of July. Most analysts, 37 of 45, rate the stock a buy, though the average target of $237 sits 8% below the current price.
Management has a perfect record of clearing its own targets by a few cents every quarter, showing they have a tight grip on the business and set bars they know they can hit.
| Expectation | |
|---|---|
| EPS | $3.25 |
| Revenue | $4.36B |
Follow IQVIA Holdings to get the latest and most important updates.
Follow IQV